2-cyclohexyl-1-(4-fluorophenyl)ethan-1-ol | 157688-87-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚酯
• 英文名称: 2-cyclohexyl-1-(4-fluorophenyl)ethan-1-ol
• 英文别名: 4-fluorophenyl cyclohexanecarboxylate；p-Fluorophenyl cyclohexanecarboxylate；(4-fluorophenyl) cyclohexanecarboxylate
• CAS: 157688-87-4
• 化学式: C₁₃H₁₅FO₂
• 分子量: 222.259
• InChiKey: VLGODGHATTYVTJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-cyclohexyl-1-(4-fluorophenyl)ethan-1-ol 在 三氯化铝 作用下， 以47%的产率得到cyclohexyl-(5-fluoro-2-hydroxyphenyl)methanone
  参考文献：
  名称：

  Krause; Rouleau; Stark, Pharmazie, 1996, vol. 51, # 10, p. 720 - 726

  摘要：

  DOI：
• 作为产物：
  描述：

  4-氟苯酚 、 环己甲酰氯 在 三乙胺 作用下， 以 乙醚 为溶剂， 反应 1.0h， 以89%的产率得到2-cyclohexyl-1-(4-fluorophenyl)ethan-1-ol
  参考文献：
  名称：

  Krause; Rouleau; Stark, Pharmazie, 1996, vol. 51, # 10, p. 720 - 726

  摘要：

  DOI：

文献信息

• Substituted alkyl amido piperidines
  申请人：Synaptic Pharmaceutical Corporation

  公开号：US20040186103A1

  公开（公告）日：2004-09-23

  This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of reducing the body mass of a subject which comprises administering to the subject an amount of a compound of the invention effective to reduce the body mass of the subject. This invention further provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject an amount of a compound of the invention effective to treat the subject's depression and/or anxiety.

  这项发明涉及选择性拮抗黑色素浓缩激素-1（MCH1）受体的化合物。该发明提供了一种包括该发明化合物的治疗有效量和药学上可接受的载体的药物组合物。该发明提供了一种由结合本发明化合物的治疗有效量和药学上可接受的载体制成的药物组合物。该发明还提供了一种制备药物组合物的方法，包括结合本发明化合物的治疗有效量和药学上可接受的载体。该发明还提供了一种减少受试者体重的方法，包括向受试者施用本发明化合物的有效量以减少受试者的体重。该发明还提供了一种治疗患有抑郁症和/或焦虑症的受试者的方法，包括向受试者施用本发明化合物的有效量以治疗受试者的抑郁症和/或焦虑症。
• Decarboxylative Conjunctive Cross‐coupling of Vinyl Boronic Esters using Metallaphotoredox Catalysis
  作者：Riccardo S. Mega、Vincent K. Duong、Adam Noble、Varinder K. Aggarwal

  DOI：10.1002/anie.201916340

  日期：2020.3.9

  The synthesis of complex alkyl boronic esters through conjunctive cross-coupling of vinyl boronic esters with carboxylic acids and aryl iodides is described. The reaction proceeds under mild metallaphotoredox conditions and involves an unprecedented decarboxylative radical addition/cross-coupling cascade of vinyl boronic esters. Excellent functional-group tolerance is displayed, and application of

  描述了通过乙烯基硼酸酯与羧酸和芳基碘化物的联合交叉偶联合成复杂的烷基硼酸酯。该反应在温和的金属光氧化还原条件下进行，并涉及乙烯基硼酸酯的前所未有的脱羧自由基加成/交叉偶联级联。显示出优异的官能团耐受性，并且一系列羧酸（包括仲 α-氨基酸和芳基碘）的应用提供了获得高度官能化烷基硼酸酯的有效途径。脱羧结合交叉偶联也应用于景天生物碱的合成。
• NHC−Iron-Catalyzed Aerobic Oxidative Aromatic Esterification of Aldehydes using Boronic Acids
  作者：João N. Rosa、R. Sudarshan Reddy、Nuno R. Candeias、Pedro M. S. D. Cal、Pedro M. P. Gois

  DOI：10.1021/ol100302e

  日期：2010.6.18

  NHC−iron complexes prepared in situ very efficiently afforded benzoates via the aerobic oxidative aromatic esterification of aldehydes with boronic acids. This method uses equimolar amounts of both the aldehyde and the boronic acid allowing the preparation of benzoates in yields up to 97%.

  原位制备的NHC-铁络合物通过醛与硼酸的好氧氧化芳族酯化反应，非常有效地提供了苯甲酸酯。该方法使用等摩尔量的醛和硼酸，使得制备苯甲酸酯的产率高达97％。
• NHC/Iron cooperative catalysis: aerobic oxidative esterification of aldehydes with phenols
  作者：R. Sudarshan Reddy、João N. Rosa、Luís F. Veiros、Stephen Caddick、Pedro M. P. Gois

  DOI：10.1039/c1ob05151b

  日期：——

  An NHC/iron cooperative catalytic system mediates the aerobic oxidative esterification of aldehydes with phenols. The use of equimolar amounts of reactants led to good to excellent isolated yields of esters.

  NHC /铁协同催化系统介导醛与酚的需氧氧化酯化。等摩尔量的反应物的使用导致酯的良好至优异的分离产率。
• [EN] SPIROCYCLIC PIPERIDINES AS MCH1 ANTAGONISTS AND USES THEREOF<br/>[FR] PIPERIDINES SPIROCYCLIQUES UTILISEES COMME ANTAGONISTES DES MCH1 ET UTILISATIONS ASSOCIEES
  申请人：SYNAPTIC PHARMA CORP

  公开号：WO2004004714A1

  公开（公告）日：2004-01-15

  This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of reducing the body mass of a subject which comprises administering to the subject an amount of a compound of the invention effective to reduce the body mass of the subject. This invention further provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject an amount of a compound of the invention effective to treat the subject=s depression and/or anxiety. This invention further provides a method of treating a subject suffering from a urinary disorder.

  这项发明涉及选择性拮抗黑色素浓缩激素-1（MCH1）受体的化合物。该发明提供了一种药物组合物，包括本发明的化合物的治疗有效量和药学上可接受的载体。该发明提供了一种通过结合本发明的化合物的治疗有效量和药学上可接受的载体制备的药物组合物。该发明还提供了一种制备药物组合物的方法，包括结合本发明的化合物的治疗有效量和药学上可接受的载体。该发明还提供了一种减少受试者体重的方法，包括向受试者投与本发明化合物的有效量以减少受试者体重。该发明还提供了一种治疗患有抑郁症和/或焦虑症的受试者的方法，包括向受试者投与本发明化合物的有效量以治疗受试者的抑郁症和/或焦虑症。该发明还提供了一种治疗患有尿液失调的受试者的方法。